EN DE
Watch Ping An Healthcare and Technology Company Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ping An Healthcare and Technology Company Ltd (1833) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Ping An Healthcare and Technology Company Ltd stock HK$3.74, price HK$5.34, that is 29.9% below the price, quality 58 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG711391022

PA Ping An Healthcare and Technology Company Ltd logo Thin data Nov 15, 2026

Ping An Healthcare and Technology Company Ltd

1833 · HK

Expensive (fair value 30% below the price) and falling price, but solid company: meets 1 of 3 rules.

Get notified free when this changes
Low debt 
Generates free cash flow 
Ranks above peers (9/14) 
Recent news very positive 
Quality 58/100 
Thin margins · 8.5% net margin (TTM) 
Fair value HK$3.74 · Overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y −4.5 %/yr in CNY) 
Narrow moat 36/100 · thin data
Thin data 
Watch Ping An Healthcare and Technology Company Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$91.20 HK$5.28 Fair Value HK$3.74 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range HK$5.28 – HK$91.20 · fair‑value band HK$2.99 – HK$4.82 · the HK$5.34 price screens above the HK$3.74 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Ping An Healthcare and Technology Company in your weekly email

Every Wednesday you see whether Ping An Healthcare and Technology Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ping An Healthcare and Technology Company Limited, together with its subsidiaries, operates an online healthcare services platform in China.

Show moreShow less

It offers online diagnosis and treatment, online consultation services, audio and video consultations, standardized healthcare service packages, health check-ups, genetic testing, concierge services, health management services, smart device sales, and consulting services.

The company also provides online consultation, hospital referral and appointment, inpatient arrangement, and second opinion services; prepaid cards and health check-up services.

The company online consultation, hospital referral, inpatient arrangement, second opinion services, electronic prescriptions, health management, prepaid packages for healthcare products and services, provision of products in the Group's health mall, advertising services, and consulting services, as well as operates an insurance agency.

In addition it is involved in the integrated finance business. The company was incorporated in 2014 and is headquartered in Shanghai, China. Ping An Healthcare and Technology Company Limited operates as a subsidiary of Glorious Peace Limited.

Stock analysis

Ping An Healthcare and Technology Company Ltd (1833) currently trades at HK$5.34, while our model-based Fair Value estimate is HK$3.74, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Dividend Discount group reads highest at a median of HK$25.09 per share, and 7 of the 26 models we run sit above the HK$5.34 price.

Bear case: the Economic Profit group reads lowest at HK$2.70, and 19 of the 26 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$2.99 (bear) to HK$4.82 (bull), the price of HK$5.34 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Ping An Healthcare and Technology Company Ltd reported revenue of 5.5B CNY in FY2025 versus 7.3B CNY in FY2021, a compound −7.1%/yr. Reported net income was 380M CNY in FY2025.

Key figures

Market cap HK$11.4B (≈ $1.4B) Small · P/E ratio 23.7 · P/S ratio 1.64 · Net margin 6.9% · Return on equity 4.7% · Return on assets (EBIT) −3.3% (5-year average) · Operating margin 8.6% · Revenue (TTM) 5.4B CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).

What moves the price

The share trades about 71% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −30%, 1833 screens richer than that median.

Fair Value models

Bear HK$2.99 Fair Value HK$3.74 Bull HK$4.82
Price HK$5.34 · Downside -29.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$3.47 HK$4.88 HK$6.99 81
Growth DCF HK$3.42 HK$4.62 HK$6.29 79
5Y EBITDA Exit HK$2.71 HK$3.47 HK$4.39 77
All 26 models by family
DCF Models
FCF DCF HK$3.47 HK$4.88 HK$6.99 81
Owner Earnings HK$4.27 HK$6.20 HK$9.09 76
5Y Revenue Exit HK$2.45 HK$2.93 HK$3.53 74
5Y EBITDA Exit HK$2.71 HK$3.47 HK$4.39 77
5Y P/E Exit HK$4.08 HK$6.34 HK$8.96 70
10Y Revenue Exit HK$2.83 HK$3.40 HK$4.18 68
10Y EBITDA Exit HK$2.99 HK$3.74 HK$4.82 70
10Y P/E Exit HK$3.79 HK$5.60 HK$8.21 63
Earnings-Based
Graham-Dodd HK$1.43 HK$7.01 HK$9.66 64
Lynch FV HK$2.69 HK$3.84 HK$4.99 61
PEG = 1.0 HK$2.69 HK$3.84 HK$4.99 57
EPV HK$1.68 HK$1.72 HK$1.76 74
Dividend Discount
Gordon GGM HK$15.14 HK$25.88 HK$34.14 68
DDM Multi-Stage HK$15.14 HK$24.29 HK$27.79 67
Multiples
P/E Multiple HK$3.46 HK$4.61 HK$5.76 63
P/S Multiple HK$2.67 HK$3.56 HK$4.45 58
P/B Multiple HK$8.34 HK$11.12 HK$13.91 55
EV/EBIT HK$1.99 HK$2.22 HK$2.45 66
EV/EBITDA HK$2.29 HK$2.62 HK$2.95 67
EV/Revenue HK$1.79 HK$2.00 HK$2.21 54
Asset-Based
NCAV (Graham) HK$1.96 HK$2.97 HK$3.71 55
Growth DCF
Growth DCF HK$3.42 HK$4.62 HK$6.29 79
Rev-Margin DCF HK$2.45 HK$2.96 HK$3.62 74
Economic Profit
Residual Income HK$3.70 HK$3.67 HK$3.76 76
ROIC Compounder HK$1.68 HK$1.72 HK$1.76 72
Growth Earnings
Growth-Adj P/E HK$2.98 HK$4.26 HK$5.53 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 58/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 28
How much profit the company makes from its sales and capital
Quality Growth 69
Are margins and returns getting better?
Cashflow 53
Do the profits arrive as real cash?
Financial strength 85
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 44
How calm the share price moves, does not count
Price momentum 5
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 23
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+13.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.5%
Start year 2020 (pandemic). Over 10 years: +34.7% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−13.4% (2020) → 1.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

Little optimism in the price
The price assumes about as much growth as the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.5%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −7.0% a year for the price and +2.8% for the forecasts.
Forecast 2026 (sales)−9.2%
Forecast 2027 (sales)+9.7%
Projected 2028 (sales)+8.7%
Projected 2029 (sales)+7.8%
Projected 2030 (sales)+6.8%

1833 screens overvalued: fair value 30% below the price. Compare with Veeva Systems Inc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (49 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare Ping An Healthcare and Technology Company Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 142 stocks

Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 58 · Above median
Fair Value upside −29.9% · Below median
Profitability
Return on equity (12 months) 4.7% · Above median
Return on assets 2.9% · Above median
Net margin (12 months) 8.5% · Above median
Operating margin (12 months) 8.6% · Above median
Growth and dividend
Revenue growth (quarter YoY) −0.7% · Below median
Balance sheet
Debt / equity 0.00× · Below median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (12 months) 23.7× · Cheaper than median
P/B 0.97× · Cheapest 25%
P/S (12 months) 1.78× · Cheaper than median
Price / free cash flow (fiscal year) 24.7× · Pricier than median
EV/EBITDA 21.6× · Pricier than median
PEG 4.37× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 16
FUTURE (revenue growth)0 · sector 43
PAST (return on equity)19 · sector 3
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 44

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $301.53 $332.66 +10% vs 1833
Doximity, Inc DOCS $33.34 $36.67 +10% vs 1833
HealthEquity, Inc HQY $103.46 $113.36 +10% vs 1833
Waystar Holding WAY $27.99 $29.10 +4% vs 1833
Tempus AI, Inc TEM $71.60 $52.58 −27% vs 1833
HeartFlow, Inc HTFL $48.46 $30.56 −37% vs 1833
Hinge Health, Inc HNGE $115.39 $51.25 −56% vs 1833
Pro Medicus Limited PME A$201.66 A$85.12 −58% vs 1833
BrightSpring Health Services, Inc BTSG $71.21 $25.72 −64% vs 1833
XtalPi Holdings 2228 HK$5.87 HK$1.53 −74% vs 1833

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ping An Healthcare and Technology Company Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ping An Healthcare and Technology Company Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1833

Frequently asked questions

Is Ping An Healthcare and Technology Company Ltd (1833) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of HK$3.74 versus a price of HK$5.34, about 30% lower (overvalued).
What is the fair value of 1833?
Our model-based fair value for Ping An Healthcare and Technology Company Ltd is HK$3.74 (as of Nov 15, 2026), built from audited fundamentals. The current price: HK$5.34.
What is the quality score of 1833?
Ping An Healthcare and Technology Company Ltd has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ping An Healthcare and Technology Company Ltd (1833)?
Our model-based price target is the fair value of HK$3.74 (as of Nov 15, 2026) from 26 valuation models. Cautious scenario HK$2.99, optimistic scenario HK$4.82. It is a calculation from audited fundamentals, not an analyst target.
What is the Ping An Healthcare and Technology Company Ltd stock forecast for 2026?
Our models put fair value at HK$3.74, about 30% lower versus a price of HK$5.34 (overvalued). Cautious scenario HK$2.99, optimistic scenario HK$4.82. The calculation is refreshed regularly with new filings.
What is the revenue of Ping An Healthcare and Technology Company Ltd (1833)?
Ping An Healthcare and Technology Company Ltd reported trailing-twelve-month revenue of about 5.4B CNY (latest available figure, as of Nov 15, 2026).
What growth is priced into Ping An Healthcare and Technology Company Ltd (1833)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at Ping An Healthcare and Technology Company Ltd shrinks by 5.5 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 4.5 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of 1833 use?
Our models discount Ping An Healthcare and Technology Company Ltd at 12.0 %: a base by market capitalisation (small), damped by beta 1.08, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ping An Healthcare and Technology Company Ltd that is -5.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has Ping An Healthcare and Technology Company Ltd (1833) delivered so far?
Over the past 5 years revenue at Ping An Healthcare and Technology Company Ltd shrank 4.5 % a year. The price currently implies free-cash-flow growth of -5.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ping An Healthcare and Technology Company Ltd (1833) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Ping An Healthcare and Technology Company Ltd (-5.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ping An Healthcare and Technology Company Ltd (1833)?
The free-cash-flow yield on the price is 4.05 %: that much free cash flow Ping An Healthcare and Technology Company Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ping An Healthcare and Technology Company Ltd (1833)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ping An Healthcare and Technology Company Ltd it is HK$3.74 per share (as of Nov 15, 2026), against a price of HK$5.34. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Ping An Healthcare and Technology Company Ltd stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 1833 trades above its calculated fair value: price HK$5.34, fair value HK$3.74, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1833?
No. The price is what the market pays today (HK$5.34); the fair value is what the company's own numbers justify (HK$3.74). For Ping An Healthcare and Technology Company Ltd the two are HK$1.60 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ping An Healthcare and Technology Company Ltd worth?
The market values Ping An Healthcare and Technology Company Ltd at about HK$11.4B (market capitalisation, as of Nov 15, 2026). Per share that is HK$5.34; our models calculate a fair value of HK$3.74 per share.
What do the bullish and bearish scenarios say about 1833?
Our models span a range for Ping An Healthcare and Technology Company Ltd: cautious scenario HK$2.99, base HK$3.74, optimistic HK$4.82 per share (as of Nov 15, 2026, price HK$5.34). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1833?
Ping An Healthcare and Technology Company Ltd trades at a price-to-earnings ratio of 23.7 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$3.74 is built from several models across several years. Other multiples: PEG 4.4, P/B 1.0, P/S 1.8, EV/EBITDA 21.6.
What is the PEG ratio of 1833?
The PEG ratio of Ping An Healthcare and Technology Company Ltd is 4.37 (P/E divided by earnings growth, as of Nov 15, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Ping An Healthcare and Technology Company Ltd (1833)?
Balance-sheet figures for Ping An Healthcare and Technology Company Ltd (as of Nov 15, 2026): return on equity 4.7%, debt of 0.00 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 1833 from its 52-week high?
Ping An Healthcare and Technology Company Ltd trades at HK$5.34, about 71% below its 52-week high of HK$18.46 and 1% above the low of HK$5.28 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$3.74 is for.
Which stocks are comparable to Ping An Healthcare and Technology Company Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ping An Healthcare and Technology Company Ltd stock attractive at the current price?
The data as of Nov 15, 2026: price HK$5.34, calculated fair value HK$3.74 (−30%), Quality Score 58/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1833 calculated?
We run Ping An Healthcare and Technology Company Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$3.74 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Ping An Healthcare and Technology Company Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ping An Healthcare and Technology Company Ltd (1833)?
The closing price on Nov 13, 2026 was HK$5.34. Our model-based fair value is HK$3.74, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ping An Healthcare and Technology Company Ltd right now?
The price sits above even our optimistic bull case (HK$4.82). The favourable scenario is already priced in. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Ping An Healthcare and Technology Company Ltd

How large is the market capitalisation of Ping An Healthcare and Technology Company Ltd (1833)?
The market capitalisation of Ping An Healthcare and Technology Company Ltd is HK$11.4B (≈ $1.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ping An Healthcare and Technology Company Ltd (1833)?
The price-to-sales ratio of Ping An Healthcare and Technology Company Ltd is 1.64 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Ping An Healthcare and Technology Company Ltd (1833)?
The net margin of Ping An Healthcare and Technology Company Ltd is 6.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ping An Healthcare and Technology Company Ltd (1833)?
The return on equity (ROE) of Ping An Healthcare and Technology Company Ltd is 4.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ping An Healthcare and Technology Company Ltd (1833)?
On an EBIT basis the return on assets of Ping An Healthcare and Technology Company Ltd is −3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ping An Healthcare and Technology Company Ltd (1833)?
The operating margin of Ping An Healthcare and Technology Company Ltd is 8.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ping An Healthcare and Technology Company Ltd (1833)?
Revenue at Ping An Healthcare and Technology Company Ltd is down 0.7% versus a year earlier (3y avg −4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ping An Healthcare and Technology Company Ltd (1833)?
Earnings per share at Ping An Healthcare and Technology Company Ltd are growing 48.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Ping An Healthcare and Technology Company Ltd (1833) hold?
Ping An Healthcare and Technology Company Ltd holds more cash than debt, 2.4B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Ping An Healthcare and Technology Company Ltd in the live analysis

One click puts Ping An Healthcare and Technology Company Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.